In a first for the U.S., the FDA has authorized the use of Pfizer’s BioNTech-partnered COVID-19 vaccine for use in adolescents between the ages of 12 and 15—months ahead of the upcoming school year in the fall. The FDA will amend the existing emergency authorization for the vaccine, which was first issued in December, the agency said. Pfizer’s… Read More »
Gary Collis of Bunker Hill, West Virginia, receives his boost dose at a coronavirus disease (COVID-19) community vaccination event, as the vaccination rate in West Virginia ranks among highest in world, in Martinsburg, February 25, 2021. Kevin Lamarque | Reuters Johnson & Johnson‘s Covid-19 vaccine can be used as a substitute for a second jab… Read More »
Pfizer’s announcement on Monday that its COVID-19 shot appears to keep nine in 10 people from getting the disease sent its stock price rocketing. Many news reports described the vaccine as if it were our deliverance from the pandemic, even though few details were released. There was certainly something to crow about: Pfizer’s vaccine consists… Read More »
With a bold prediction that interim data on its COVID-19 shot would be in the public’s hands by October, all eyes have been on Pfizer and CEO Albert Bourla. But with just days to go before November, those data still aren’t available—and Pfizer is holding on to hope that it can still roll out the… Read More »
The mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not be a good thing, analysts say. Earlier this week, the New York drugmaker agreed to merge its off-patent drugs business, dubbed Upjohn, with Mylan,… Read More »